边缘区淋巴瘤研究进展  

Progress of marginal zone lymphoma

作　　者：杜心怡[1] 范磊[1] 李建勇[1] 

机构地区：[1]南京医科大学第一附属医院江苏省人民医院血液科,210029

出　　处：《白血病．淋巴瘤》2017年第1期24-27,共4页Journal of Leukemia & Lymphoma

基　　金：江苏省优秀青年基金（BK20160099）;江苏省六大高峰人才（2015-WSN-050）

摘　　要：边缘区淋巴瘤（MZL）约占非霍奇金淋巴瘤的10％，可以分为黏膜相关淋巴组织（MALT）淋巴瘤、淋巴结MZL及脾脏MZL，其中以MALT淋巴瘤最为常见，约占非霍奇金淋巴瘤的7．5％。2016年第58届美国血液学会（ASH）年会关于MZL研究进展的报告涵盖从基础研究到临床诊疗多个方面：基于流式细胞学、细胞遗传学和荧光原位杂交（FISH）等技术对MZL的发病机制的研究进一步深入，新型预后指数系统的提出有助于对MZL患者分级并指导治疗，治疗方案的变化及新药的加入能够进一步提高此类患者的临床疗效和安全性。Marginal zone lymphoma （MZL） accounts for approximately 10 % of non-Hodgkin lymphoma （NHL）. It can be divided into three specific entities： extranodal marginal zone lymphoma of mucosaassociated lymphoid tissue （MALT lymphoma）, nodal marginal zone lymphoma （NMZL） and splenic marginal zone lymphoma （SMZL）. MALT lymphoma is the most frequent overall, representing 7.5 % of all NHLs. Reports on research progress of MZL in the 58th American Society of Hematology Annual Meeting covered multiple respects which ranged from basic research to clinical prognosis and treatment. Based on the technology such as flow cytometry, cytogeneties and FISH, further study on pathogenesis of MZL is developing, and new prognostic index system can help to stratify patients more exactly and give a guidance to treatment. What＇s more, the change of therapy and new drugs will benefit to the clinical efficacy and safety of MZL patients.

关 键 词：淋巴瘤 边缘区 美国血液学会年会 

分 类 号：R733.1[医药卫生—肿瘤]